title: Frequency of hyperprolactinemia and its associations with demographic and clinical characteristics and antipsychotic medications in psychiatric inpatients in China.
abstract: OBJECTIVE
  No study has investigated hyperprolactinemia and its risk factors in Chinese psychiatric patients. This study examined the prevalence of hyperprolactinemia and its relationship with demographic and clinical characteristics in inpatients in a large psychiatric institution in Beijing, China.
  
  
  METHODS
  A consecutive sample of 617 psychiatric inpatients formed the study sample. Basic sociodemographic and clinical data including serum prolactin level were collected.
  
  
  RESULTS
  The prevalence of hyperprolactinemia was 55.9% in the whole sample, and 56.8% and 43.2% for women and men, respectively. The corresponding figures were 59.6%, 40.0%, 53.6%, and 50.8% in schizophrenia spectrum disorders, major depression, bipolar disorders, and other psychiatric disorders, respectively (p = 0.09). In univariate analyses, patients having hyperprolactinemia were younger, more likely to receive risperidone, amisulpride, and first-generation antipsychotics, but less likely to receive clozapine and aripiprazole. In multiple logistic regression analysis, hyperprolactinemia was independently associated with younger age, more use of risperidone or amisulpride and first-generation antipsychotics, and less use of clozapine and aripiprazole (r(2) = 0.197).
  
  
  CONCLUSIONS
  Hyperprolactinemia is very common in Chinese psychiatric inpatients. Given the potentially harmful consequences of hyperprolactinemia and its preventable nature, effective measures to lower the frequency hyperprolactinemia in patients with major psychiatric disorders should be implemented in Chinese mental health facilities.
authors.affiliation: Beijing Anding Hospital, Capital Medical University, Beijing, China.
authors.forename: Zhi-Min
authors.initials: ZM
authors.lastname: Wang
authors.forename: Yu-Tao
authors.initials: YT
authors.lastname: Xiang
authors.forename: Feng-Rong
authors.initials: FR
authors.lastname: An
authors.forename: Christoph U
authors.initials: CU
authors.lastname: Correll
authors.forename: Gabor S
authors.initials: GS
authors.lastname: Ungvari
authors.forename: Chuan-Yue
authors.initials: CY
authors.lastname: Wang
authors.forename: Kelly Y C
authors.initials: KY
authors.lastname: Lai
authors.forename: Qi-Jing
authors.initials: QJ
authors.lastname: Bo
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.forename: Bao-Liang
authors.initials: BL
authors.lastname: Zhong
authors.forename: Helen F K
authors.initials: HF
authors.lastname: Chiu
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D000068476:Beijing / Q000453:epidemiology; D005260:Female; D006778:Hospitals, Psychiatric / Q000706:statistics & numerical data; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced* / Q000453:epidemiology; D007297:Inpatients / Q000706:statistics & numerical data; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy* / Q000453:epidemiology; D008875:Middle Aged
chemical_list: D014150:Antipsychotic Agents
keywords: Antipsychotic medication; China; hyperprolactinaemia